** Shares of drug developer Milestone Pharmaceuticals MIST.O fall 8% to 73 cents, extending decline to third day
** Brokerage TD Cowen downgrades MIST to "hold" from "buy", removes PT
** Cites etripamil's regulatory and commercial timing uncertainty
** "The lack of clarity on regulatory timelines puts additional strain on the company's limited capital," says brokerage
** MIST shares fell ~61% on Friday after the U.S. FDA declined to approve its nasal spray, Cardamyst, to treat a type of heart condition
** Including session moves, MIST stock down ~69% YTD compared to ~5% decline in the S&P 500 index .SPX
(Reporting by Ateev Bhandari in Bengaluru)
((Ateev.Bhandari@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。